China NT Pharma Group Company Limited (1011.HK)
HKD 0.41
(-7.87%)
HKD 0.41
(-7.87%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | - CNY | -404.87% |
| 2022 | 18.43 Million CNY | 131.1% |
| 2021 | -59.27 Million CNY | 13.0% |
| 2020 | -68.13 Million CNY | -209.04% |
| 2019 | -22.04 Million CNY | 91.06% |
| 2018 | -246.56 Million CNY | -191.46% |
| 2017 | 269.57 Million CNY | 45.2% |
| 2016 | 185.66 Million CNY | 36.56% |
| 2015 | 135.95 Million CNY | 41.52% |
| 2014 | 96.07 Million CNY | 116.63% |
| 2013 | -577.63 Million CNY | 48.3% |
| 2012 | -1.11 Billion CNY | -405.62% |
| 2011 | 365.55 Million CNY | 43.05% |
| 2010 | 255.53 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -1.39 Million CNY | 0.0% |
| 2023 Q2 | -2.74 Million CNY | 0.0% |
| 2023 FY | -56.2 Million CNY | -404.87% |
| 2022 Q4 | 19.15 Million CNY | 0.0% |
| 2022 Q2 | -236 Thousand CNY | 0.0% |
| 2022 FY | 18.43 Million CNY | 131.1% |
| 2021 FY | -59.27 Million CNY | 13.0% |
| 2021 Q4 | -76.66 Million CNY | 0.0% |
| 2021 Q2 | -16.8 Million CNY | 0.0% |
| 2020 Q2 | -24.66 Million CNY | 0.0% |
| 2020 FY | -68.13 Million CNY | -209.04% |
| 2019 FY | -22.04 Million CNY | 91.06% |
| 2019 Q2 | -22.24 Million CNY | 0.0% |
| 2018 FY | -246.56 Million CNY | -191.46% |
| 2018 Q4 | - CNY | 0.0% |
| 2018 Q2 | 138.71 Million CNY | 0.0% |
| 2017 Q2 | 141.6 Million CNY | 0.0% |
| 2017 Q4 | - CNY | 0.0% |
| 2017 FY | 269.57 Million CNY | 45.2% |
| 2016 Q2 | 57.89 Million CNY | 0.0% |
| 2016 Q4 | - CNY | 0.0% |
| 2016 FY | 185.66 Million CNY | 36.56% |
| 2015 FY | 135.95 Million CNY | 41.52% |
| 2015 Q2 | 60.61 Million CNY | 0.0% |
| 2015 Q4 | 76.85 Million CNY | 0.0% |
| 2014 Q4 | 44.05 Million CNY | 0.0% |
| 2014 FY | 96.07 Million CNY | 116.63% |
| 2014 Q2 | 34.43 Million CNY | 0.0% |
| 2013 Q4 | -80.19 Million CNY | 0.0% |
| 2013 FY | -577.63 Million CNY | 48.3% |
| 2013 Q2 | -94.56 Million CNY | 0.0% |
| 2012 Q2 | - CNY | 0.0% |
| 2012 FY | -1.11 Billion CNY | -405.62% |
| 2012 Q4 | - CNY | 0.0% |
| 2011 FY | 365.55 Million CNY | 43.05% |
| 2011 Q4 | - CNY | 0.0% |
| 2011 Q2 | - CNY | 0.0% |
| 2010 FY | 255.53 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 143.01 Million HKD | 100.0% |
| Grand Pharmaceutical Group Limited | 2.66 Billion HKD | 100.0% |
| Extrawell Pharmaceutical Holdings Limited | -8.16 Million HKD | 100.0% |
| Wai Yuen Tong Medicine Holdings Limited | 40.88 Million HKD | 100.0% |
| Qianhai Health Holdings Limited | -52.18 Million HKD | 100.0% |
| Lee's Pharmaceutical Holdings Limited | 36.04 Million HKD | 100.0% |
| Essex Bio-Technology Limited | 310.32 Million HKD | 100.0% |
| Tongfang Kontafarma Holdings Limited | - HKD | NaN% |
| PuraPharm Corporation Limited | -66.04 Million HKD | 100.0% |
| SSY Group Limited | 1.63 Billion HKD | 100.0% |
| JBM (Healthcare) Limited | 174.2 Million HKD | 100.0% |
| Jacobson Pharma Corporation Limited | 333.12 Million HKD | 100.0% |
| China Resources Pharmaceutical Group Limited | 12.14 Billion HKD | 100.0% |